Complications of Antipsychotic Therapy in Children With Tourette Syndrome

Pediatric Neurology

Volumn 43, Issue 1, 2010, Pages 17-20

  Pringsheim, Tamara ^a   Pearce, Michelle ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENT; AKATHISIA; ARTICLE; BODY MASS; CHILD; CHILD GROWTH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DYSLIPIDEMIA; DYSTONIA; FEMALE; FOLLOW UP; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; OBSESSIVE COMPULSIVE DISORDER; PARKINSONISM; PATIENT MONITORING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCHOOL CHILD; SEX DIFFERENCE; TARDIVE DYSKINESIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY COMPOSITION; CHILD; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; MALE; RISK FACTORS; TOURETTE SYNDROME;

EID: 77952964364     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2010.02.012     Document Type: Article

References (20)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text revision (2000), American Psychiatric Association, Washington, DC
2. Freeman R.D., Fast D.K., Burd L., Kerbeshian J., Robertson M.M., and Sandor P. An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries. Dev Med Child Neurol 42 (2000) 436-447
3. Scahill L., Erenberg G., Berlin Jr. C.M., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3 (2006) 192-206
4. Fedorowicz V., and Fombonne E. Metabolic side effects of atypical antipsychotics in children: A literature review. J Psychopharmacol 19 (2005) 533-550
5. Fraguas D., Merchan-Naranjo J., Laita P., Parellada M., and Moreno D. Metabolic and hormonal side effects in children and adolescents treated with second generation antipsychotics. J Clin Psychiatry 69 (2008) 1166-1175
6. McIntyre R., and Jerrell J. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 162 (2008) 929-935
7. Correll C., Manu P., Olshansky V., Napolitano B., Kane J., and Malhotra A. Cardiometabolic risk of second generation antipsychotic medications during first time use in children and adolescents. JAMA 302 (2009) 1765-1773
8. Sethi K., and Morgan J. Drug-induced movement disorders. In: Jankovic J., and Tolosa E. (Eds). Parkinson's disease and movement disorders (2007), Lippincott Williams and Wilkins, Philadelphia 394-408
9. Leucht S., Corves C., Arbter D., Engel R., and Li C. Second generation versus first generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 373 (2009) 31-41
10. Pierre J. Extrapyramidal symptoms with atypical antipsychotics. Drug Saf 28 (2005) 191-208
11. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (1992) 525-584
12. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 32 Suppl. (2008) S1-201
13. Lambert M., Delvin E., Levy E., O'Loughlin J., and Paradis G. Prevalence of cardiometabolic risk factors by weight status in a population based sample of Quebec children and adolescents. Can J Cardiol 24 (2008) 575-583
14. Kuczmarski R.J., Ogden C.L., Guo S.S., et al. 2000 CDC growth charts for the United States: Methods and development. Vital Health Stat 246 (2002) 1-190
15. Dai S., Fulton J., Harrist R., Grunbaum J., Steffen L., and Labarthe D. Blood lipids in children: Age related patterns and association with body-fat indices. Am J Prev Med 37 Suppl (2009) S56-S64
16. Mattson N., Ronnemaa T., Juonala M., Viikari J., and Raitakari O. Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study. Ann Med 40 (2008) 542-552
17. Al Mamun A., Cramb S., O'Callaghan M., William G., and Najman J. Childhood overweight status predicts diabetes at age 21 years: A follow-up study. Obesity 17 (2009) 1255-1261
18. Juonala M., Jarvisalo M., Maki-Torkko N., Kahonen M., Viikari J., and Raitakari O. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood. Circulation 112 (2005) 1486-1493
19. Pulkki-Raback L., Elovainio M., Kivimaki M., Mattson N., and Raitakairi O. Depressive symptoms and the metabolic syndrome in childhood and adulthood: A prospective cohort study. Health Psychol 28 (2009) 108-116
20. Daniels S.R., and Greer F.R. Lipid screening and cardiovascular health in childhood. Pediatrics 122 (2008) 198-208